WallStSmart

ICU Medical Inc (ICUI)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2949% more annual revenue ($65.77B vs $2.16B). MRK leads profitability with a 13.6% profit margin vs 2.1%. ICUI appears more attractively valued with a PEG of 0.08. MRK earns a higher WallStSmart Score of 50/100 (D+).

ICUI

Hold

48

out of 100

Grade: D+

Growth: 2.0Profit: 4.5Value: 7.3Quality: 6.5
Piotroski: 4/9Altman Z: 1.74

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICUIUndervalued (+54.6%)

Margin of Safety

+54.6%

Fair Value

$325.54

Current Price

$136.61

$188.93 discount

UndervaluedFair: $325.54Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICUI2 strengths · Avg: 9.0/10
PEG RatioValuation
0.0810/10

Growing faster than its price suggests

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ICUI4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.744/10

Distress zone — elevated risk

Return on EquityProfitability
2.2%3/10

ROE of 2.2% — below average capital efficiency

Profit MarginProfitability
2.1%3/10

2.1% margin — thin

P/E RatioValuation
76.5x2/10

Premium valuation, high expectations priced in

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ICUI

The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.08 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ICUI

The primary concerns for ICUI are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 76.5x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ICUI carries more volatility with a beta of 0.78 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 48/100). ICUI offers better value entry with a 54.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICU Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?